Schizophrenia Research
Volume 101, Issue 1 , Pages 256-265 , April 2008

Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes

  • Julie Kreyenbuhl

      Affiliations

    • Division of Services Research, Department of Psychiatry, University of Maryland School of Medicine, 737 W. Lombard Street, 5th floor, Baltimore, MD, 21201, United States
    • VA Capitol Healthcare Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), 10 N. Greene St. (BT/MIRECC), Baltimore, MD, 21201, United States
    • Corresponding Author InformationCorresponding author. University of Maryland School of Medicine, Department of Psychiatry, Division of Services Research, 737 W. Lombard Street, 5th floor, Baltimore, MD 21201, United States. Tel.: +1 410 605 7466; fax: +1 410 605 7739.
    • ,
  • Deborah R. Medoff

      Affiliations

    • Division of Services Research, Department of Psychiatry, University of Maryland School of Medicine, 737 W. Lombard Street, 5th floor, Baltimore, MD, 21201, United States
    • VA Capitol Healthcare Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), 10 N. Greene St. (BT/MIRECC), Baltimore, MD, 21201, United States
    • ,
  • Stephen L. Seliger

      Affiliations

    • Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, 22 S. Greene St., N3W143, Baltimore, MD, 21201, United States
    • ,
  • Lisa B. Dixon

      Affiliations

    • Division of Services Research, Department of Psychiatry, University of Maryland School of Medicine, 737 W. Lombard Street, 5th floor, Baltimore, MD, 21201, United States
    • VA Capitol Healthcare Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), 10 N. Greene St. (BT/MIRECC), Baltimore, MD, 21201, United States

Received 6 November 2007 ,Revised 5 February 2008 ,Accepted 7 February 2008.

References 

  1. American Diabetes Association . Standards of medical care in diabetes. Diabetes Care. 2007;30(Suppl 1):S4–S41
  2. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br. J. Psychiatry. 2000;177(3):212–217
  3. Colton, C.W., Manderscheid, R.W., 2006. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chronic. Dis. [serial online] [Accessed: October 30, 2007]. Available from: URL: http://www.cdc.gov/pcd/issues/2006/apr/05_0180.htm.
  4. Cooke CE, Fatodu H. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a Medicaid managed care organization. J. Manag. Care Pharm. 2006;12(8):649–655
  5. Daumit GL, Clark JM, Steinwachs DM, Graham CM, Lehman A, Ford DE. Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. J. of Nerv. Ment. Dis. 2003;191(12):799–805
  6. Daumit GL, Goldberg RW, Anthony C, Dickerson F, Brown CH, Kreyenbuhl J, et al. Physical activity patterns in adults with severe mental illness. J. of Nerv. Ment. Dis. 2005;193(10):641–646
  7. de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am. J. Psychiatry. 1995;152(3):453–455
  8. Dixon LB, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 2000;26(4):903–912
  9. Dixon LB, Kreyenbuhl JA, Dickerson FB, Donner TW, Brown CH, Wohlheiter K, et al. A comparison of Type 2 diabetes outcomes among persons with and without severe mental illness. Psychiatr. Serv. 2004;55(8):892–900
  10. Dixon LB, Adler DA, Berlant JL, Dulit RA, Goldman B, Hackman AL, et al. Psychiatrists and primary caring: what are our boundaries of responsibility?. Psychiatr. Serv. 2007;58(5):600–602
  11. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, et al. Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks: management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch. Intern. Med. 2003;163(5):525–541
  12. Egede LE, Dagogo-Jack S. Epidemiology of type 2 diabetes: focus on ethnic minorities. Med. Clin. North Am. 2005;89(5):949–975
  13. Essock SM, Dowden S, Constantine NT, Katz L, Swartz MS, Meador KG, et al. Risk factors for HIV, hepatitis B, and hepatitis C among persons with severe mental illness. Psychiatr. Serv. 2003;54(6):836–841
  14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497
  15. Frayne SM, Halanych JH, Miller DR, Wang F, Lin H, Pogach L, et al. Disparities in diabetes care: impact of mental illness. Arch. Intern. Med. 2005;165(22):2631–2638
  16. Garcia-Unzueta MT, Herran A, Sierra-Biddle D, Amado JA, Vazquez-Barquero JL, Alvarez C. Alterations of liver function test in patients treated with antipsychotics. J. Clin. Lab. Anal. 2003;17(6):216–218
  17. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 2005;80(1):45–53
  18. Goldberg RW, Kreyenbuhl J, Dickerson FB, Wohlheiter K, Fang LJ, Brown CH, et al. Quality of diabetes care among adults with serious mental illness. Psychiatr. Serv. 2007;58(4):536–543
  19. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in US academic medical centers. Diabetes Care. 2005;28(2):337–442
  20. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann. Intern. Med. 2006;145(7):520–530
  21. Krein SL, Bingham CR, McCarthy JF, Mitchinson A, Payes J, Valenstein M. Diabetes treatment among VA patients with comorbid serious mental illness. Psychiatr. Serv. 2006;57(7):1016–1021
  22. Kreyenbuhl J, Dickerson FB, Medoff DR, Brown CH, Goldberg RW, Fang L, et al. Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. J. of Nerv. Ment. Dis. 2006;194(6):404–410
  23. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br. J. Psychiatry. 2003;183(6):534–539
  24. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005;80(1):19–32
  25. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care. 2004;27(Suppl 2):B10–B21
  26. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 2006;86(1–3):15–22
  27. Nau DP, Mallya U. Sex disparity in the management of dyslipidemia among patients with type 2 diabetes mellitus in a managed care organization. Am. J. Manag. Care. 2005;11(2):69–73
  28. Nau DP, Garber MC, Herman WH. The intensification of drug therapy for diabetes and its complications: evidence from 2 HMOs. Am. J. Manag. Care. 2004;10(2 Pt 2):118–123
  29. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93
  30. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr. Res. 2000;45(1–2):21–28
  31. Rosen AB. Indications for and utilization of ACE inhibitors in older individuals with diabetes. Findings from the National Health and Nutrition Examination Survey 1999 to 2002. J. Gen. Intern. Med. 2006;21(4):315–319
  32. Rosen AB, Karter AJ, Liu JY, Selby JV, Schneider EC. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. J. Gen. Intern. Med. 2004;19(6):669–675
  33. Safford M, Eaton L, Hawley G, Brimacombe M, Rajan M, Li H, et al. Disparities in use of lipid-lowering medications among people with Type 2 diabetes mellitus. Arch. Intern. Med. 2003;163(8):922–928
  34. Sequist TD, Adams A, Zhang F, Ross-Degnan D, Ayanian JZ. Effect of quality improvement on racial disparities in diabetes care. Arch. Intern. Med. 2006;166(6):675–681
  35. Weiss AP, Henderson DC, Weilburg JB, Goff DC, Meigs JB, Cagliero E, et al. Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatr. Serv. 2006;57(8):1145–1152
  36. Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am. J. Kidney Dis. 2005;46(6):1080–1087

PII: S0920-9964(08)00096-0

doi: 10.1016/j.schres.2008.02.004

Schizophrenia Research
Volume 101, Issue 1 , Pages 256-265 , April 2008

Article Tools

* Image Usage & Resolution